Cite
MLA Citation
Jean-Charles Soria et al.. “Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.” Lancet oncology, vol. 16, no. 8, n.d., pp. 897–907. http://access.bl.uk/ark:/81055/vdc_100025994464.0x000048